The US-based firm installed a new high-speed blister packaging line to complement its existing automated bottling line at the plant
Catalent Shiga Facility. (Credit: PRNewswire/ Catalent)
Catalent, a provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and cell and gene therapies, has expanded its primary packaging capabilities at its clinical supply facility in Shiga, Japan.
The US-based firm installed a new high-speed blister packaging line to complement its existing automated bottling line at the plant.
Catalent said that the new blister packing machinery is similar to that available across the company’s clinical supply services network, providing maximum access and flexibility to customers.
The company inaugurated the 6,000m² Shiga facility in October last year to assist clients locally and internationally.
The facility offers flexible clinical supply solutions, including Catalent’s FastChain demand-led supply, white glove handling, and logistics.
Customers can use Shiga’s bilingual project and clinical supply management, packing and labelling, storage and distribution, handling of restricted drugs and cold chains, in-country returns, and services for destruction.
Catalent Clinical Supply Services Asia Pacific vice president and general manager Roel de Nobel said: “The demand for primary packaging in Japan is very high, and customers are increasingly looking for integrated providers of clinical supply expertise and services.
“Shiga is a key hub within our Asia-Pacific clinical supply services network, and with these new capabilities, which are now fully operational, we will offer a comprehensive range of services, which are customizable to customers’ specific needs.”
Catalent has a network that spans the US, the UK, Germany, Singapore, Japan, and China, in addition to more than 50 additional global depots.
The company claims that its clinical supply services are able to handle a wide range of international compliance and distribution requirements to support international clinical trials.
In May this year, the firm announced its plans to invest $175m to expand the production capabilities for large-scale oral dose forms in Winchester, Kentucky.